Susquehanna International Group
GEVA

Susquehanna International Group’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Susquehanna International Group’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-244,500
Closed -$23.8M – 10813
2015
Q1 		$23.8M Buy
244,500
+162,100
+197% +$17.2M 0.01% 1108
2014
Q4 		$7.65M Sell
82,400
-34,300
-29% -$2.71M ﹤0.01% 2322
2014
Q3 		$8.03M Sell
116,700
-100,900
-46% -$7.23M ﹤0.01% 2362
2014
Q2 		$22.8M Buy
217,600
+57,000
+35% +$4.85M 0.01% 1277
2014
Q1 		$13.3M Buy
160,600
+145,700
+978% +$13.5M 0.01% 1680
2013
Q4 		$964K Buy
14,900
+6,100
+69% +$362K ﹤0.01% 5578
2013
Q3 		$557K Sell
8,800
-5,400
-38% -$266K ﹤0.01% 6255
2013
Q2 		$596K Buy
+14,200
New +$647K ﹤0.01% 5791

Susquehanna International Group's GEVA Position: Q2 2015 in Review

Susquehanna International Group sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 6,944 shares — an estimated $677K sold.

Susquehanna International Group first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $1.9M in Q4 2013. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Susquehanna International Group reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Susquehanna International Group sold 6,944 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $677K.
  • Susquehanna International Group first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Susquehanna International Group's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.9M in Q4 2013.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Susquehanna International Group's 13F filing for Q2 2015, filed 14 Aug 2015.